Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer

整合变革方法来识别和针对癌症的新弱点

基本信息

  • 批准号:
    10457896
  • 负责人:
  • 金额:
    $ 102.55万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-08-09 至 2023-07-31
  • 项目状态:
    已结题

项目摘要

SUMMARY The last decade has seen an unparalleled pace of cancer-focused discovery enabled by disruptive technologies. However, for many malignancies, such as acute myeloid leukemia (AML), survival of the disease remains unchanged despite a more granular description of its genomic landscape. My research program seeks to apply new approaches in functional genomics and chemical biology to validate and translate emerging cancer dependencies in AML and other malignancies defined by simple genomes, particularly pediatric cancers. In this proposal, I build upon our past success in 1) inventing new approaches to small-molecule discovery 2) applying state-of-the-art chemical and functional genomic screens to identify new therapeutic targets in leukemia, Ewing sarcoma, and neuroblastoma, and in 3) translating our discoveries to clinical trials for patients suffering from these diseases. Primarily focusing on AML, my future research program seeks to 1) deploy genetic approaches to validate candidate cancer dependencies, 2) discover and test new small- molecule inhibitors of cancer dependencies, and 3) dissect the mechanisms of each target and its role in AML. I will begin with the study of targets that have emerged in our research as relevant in high-risk AML subtypes: the cytoplasmic kinase spleen tyrosine kinase (SYK); a serine-threonine kinase glycogen synthase kinase 3 alpha (GSK-3α), a mitochondrial enzyme involved in folate metabolism, methylenetetrahydrofolate dehydrogenase 2 (MTHFD2); and a member of the cohesin complex: stromal antigen 2 (STAG2). In some cases, such as Ewing sarcoma and STAG2, I will extend testing to other disease contexts where the target is relevant and my laboratory has expertise. With deep expertise in the molecular pathogenesis and care of patients with AML; experience leading highly multi-disciplinary teams focused on high-throughput screening for this disease and a rich network of chemistry, biology, and clinical collaborators, I am uniquely positioned to succeed in the 7 year research plan delineated in this proposal.
总结 在过去的十年里,以癌症为重点的发现以前所未有的速度发展, 技术.然而,对于许多恶性肿瘤,如急性髓性白血病(AML),疾病的生存期 保持不变,尽管对其基因组景观进行了更精细的描述。我的研究计划 应用功能基因组学和化学生物学的新方法来验证和翻译新兴的 AML和其他由简单基因组定义的恶性肿瘤中的癌症依赖性,特别是儿科 癌的在这个建议中,我建立在我们过去的成功基础上:1)发明小分子药物的新方法, 发现2)应用最先进的化学和功能基因组筛选来鉴定新的治疗药物 白血病、尤文肉瘤和神经母细胞瘤的靶点,并将我们的发现转化为临床试验 对于患有这些疾病的患者。我未来的研究计划主要集中在AML上,目的是1) 部署遗传方法来验证候选癌症依赖性,2)发现和测试新的小- 癌症依赖性的分子抑制剂,和3)剖析每个靶点的机制及其在AML中的作用。 我将开始研究我们研究中出现的与高危AML亚型相关的靶点: 细胞质激酶脾酪氨酸激酶(SYK);丝氨酸-苏氨酸激酶糖原合成酶激酶3 GSK-3α,一种参与叶酸代谢的线粒体酶,亚甲基四氢叶酸 脱氢酶2(MTHFD 2);和粘着蛋白复合物的成员:基质抗原2(STAG 2)。在一些 在某些情况下,如尤文肉瘤和STAG 2,我将把测试扩展到其他疾病的情况下, 我的实验室有专业知识。在分子发病机制和护理方面具有深厚的专业知识, AML患者;拥有领导高度多学科团队的经验,专注于高通量筛查, 这种疾病和丰富的化学,生物学和临床合作者网络,我处于独特的地位, 成功完成本提案中所述的7年研究计划。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kimberly Stegmaier其他文献

Kimberly Stegmaier的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kimberly Stegmaier', 18)}}的其他基金

Targeting Pediatric Cancer Vulnerabilities
针对儿童癌症的脆弱性
  • 批准号:
    10737704
  • 财政年份:
    2023
  • 资助金额:
    $ 102.55万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10688405
  • 财政年份:
    2022
  • 资助金额:
    $ 102.55万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    9600133
  • 财政年份:
    2018
  • 资助金额:
    $ 102.55万
  • 项目类别:
Targeting SYK Kinase in AML
在 AML 中靶向 SYK 激酶
  • 批准号:
    10220876
  • 财政年份:
    2017
  • 资助金额:
    $ 102.55万
  • 项目类别:
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics
用综合基因组学剖析尤文肉瘤的发病机制
  • 批准号:
    10064577
  • 财政年份:
    2017
  • 资助金额:
    $ 102.55万
  • 项目类别:
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
整合变革方法来识别和针对癌症的新弱点
  • 批准号:
    10225613
  • 财政年份:
    2016
  • 资助金额:
    $ 102.55万
  • 项目类别:
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
整合变革方法来识别和针对癌症的新弱点
  • 批准号:
    9981667
  • 财政年份:
    2016
  • 资助金额:
    $ 102.55万
  • 项目类别:
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
整合变革方法来识别和针对癌症的新弱点
  • 批准号:
    9328023
  • 财政年份:
    2016
  • 资助金额:
    $ 102.55万
  • 项目类别:
Targeting BET-bromodomains in neuroblastoma
靶向神经母细胞瘤中的 BET-溴结构域
  • 批准号:
    9066220
  • 财政年份:
    2015
  • 资助金额:
    $ 102.55万
  • 项目类别:
Validating Syk as a Target for AML Therapy
验证 Syk 作为 AML 治疗靶点
  • 批准号:
    8296670
  • 财政年份:
    2009
  • 资助金额:
    $ 102.55万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 102.55万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 102.55万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 102.55万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 102.55万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 102.55万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 102.55万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 102.55万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 102.55万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 102.55万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 102.55万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了